Promising Developments in Parkinson’s Disease Treatment with Anavex Life Sciences
In a significant stride towards addressing the unmet needs of Parkinson’s disease dementia (PDD) patients, Anavex Life Sciences has announced positive results from their phase 2 extension study of ANAVEX2-73, also known as blarcamesine. Anavex’s investigational drug has shown both safety and efficacy in improving symptoms associated with PDD, offering hope to many patients worldwide.…